ClinicalTrials.gg
Not yet recruitingNCT07946913Updated Nov 18, 2026

A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite Treatment With H1 Antihistamines

A Phase 3 interventional study of LP-003 Injection and Omalizumab in Chronic Spontaneous Urticaria (CSU), sponsored by Longbio Pharma. Not yet recruiting at 2 sites in China. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Longbio Pharma · Phase 3, Interventional, and Treatment

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
514
Allocation
Randomized
Ages
12 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 35 studies in Chronic Urticaria with a site in China — 17 open to participants now, 21 under way, 6 of them phase 3. Chronic Urticaria · China.

Planned enrollment
2nd of 31
514 · median 120
Started
2026
with 11 others
Phase 3
9 of 35
2 open now
Primary completion
2028-03
later than 19 of 20 live
Registered
35th of 35
by date
Lead sponsor
4 of 35
Longbio Pharma

Among the 35 studies in Chronic Urticaria with a site in China, this one is the 2nd largest by planned enrollment of the 31 interventional ones that give a count, is one of 12 that started in 2026, is one of 9 in phase 3, reaches primary completion later than 19 of the 20 other live ones, and was the 35th registered.

Chronic Urticaria

199 studies on the registry are indexed under Chronic Urticaria; 51 are open to participants now.

Browse Chronic Urticaria studies →

Open to participants now

17 of the 35 studies in Chronic Urticaria with a site in China are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 25 Chronic Urticaria studies recruiting now, 11 (44%) set no upper age limit and 10 (40%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.

This study: 12 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Chronic Urticaria with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, active-controlled Phase III clinical study to evaluate the safety and efficacy of LP-003 injection in patients with chronic spontaneous urticaria who remain symptomatic despite treatment with H1 antihistamines.

03

Conditions studied

  • Chronic Spontaneous Urticaria (CSU)

Browse trials for

04

Who can participate

Ages eligible
12 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have the capacity to understand the study and voluntarily signs the form (ICF);
  2. Male or female participant must be 12 to 75 years old at the time of ICF signature;
  3. Duration of chronic spontaneous urticaria (CSU) ≥ 6 months prior to screening;
  4. Presence of pruritus and wheals for at least 6 consecutive weeks before screening despite treatment with H1-AH;
  5. Participants have been on a stable dose of second-generation H1-AH as specified in the protocol for ≥2 weeks prior to randomization and within the 7 days before randomization, the UAS7( range 0-42) ≥16 and ISS7(range 0-21) ≥8;
  6. Participants must not miss UAS scores for more than one day within the 7 days prior to randomization, and are willing and able to complete daily symptom diaries during the study period.
  7. Female participants of , and male participants (and their female partners), must use one or more effective measures from the screening period until at least 6 months after the last administration of product. Participants must have no plans for pregnancy, sperm donation or oocyte donation from screening until at least 6 months after the last dose of investigational product.

Exclusion criteria

Exclusion Criteria:

  1. The subject has a primary or sole trigger for chronic urticaria (chronic Induced urticaria), including artificial urticaria (Symptomatic Dermographism), cold, heat, sun, pressure, delayed pressure, water, cholinergic, or contact urticaria;
  2. Other medical conditions accompanied by symptoms of urticaria or angioedema including, but not limited to, urticarial vasculitis, mastocytosis, pigmented urticaria, erythema multiforme, , hereditary or acquired angioedema, etc;
  3. Any other dermatologic condition with chronic itching, such as atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus or psoriasis, which in the judgment of the Investigator may affect the evaluation of the study and the results of the study;
  4. Body weight \< 40 kg
  5. Not enough washing-out period for previous therapy before randomization.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
514 participants (estimated)

Study arms

  • Experimental
    LP-003 group

    Participants received LP-003 subcutaneously during the 48-week treatment period

    Biological: LP-003 Injection

  • Active comparator
    Omalizumab group

    Participants received omalizumab subcutaneously during the 48-week treatment period

    Biological: Omalizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in weekly Urticaria Activity Score (UAS7) at week 12

    The UAS7 is a composite score derived from the ISS7 and the HSS7, i.e., the sum of ISS7 and HSS7, ranging from 0 to 42 points. UAS7 = 0 indicates complete resolution of urticaria.

    Time frame: Week 12

Secondary outcomes

  1. Change from baseline in UAS7 at each assessment visit (excluding Week 12)

    Time frame: up to approximately 56 weeks

  2. The proportion of participants with UAS7 = 0 at each assessment visit

    Time frame: up to approximately 56 weeks

  3. The proportion of participants with UAS7 ≤ 6at each assessment visit

    Time frame: up to approximately 56 weeks

  4. Change From Baseline in weekly hives severity score (HSS7) at each assessment visit.

    The HSS7 is the sum of daily HSS scores over the 7 days prior to the visit, ranging from 0 to 21 points. HSS7 = 0 indicates complete resolution of hives.

    Time frame: up to approximately 56 weeks

  5. Change From Baseline in weekly itch severity score ( ISS7) at each assessment visit.

    The ISS7 is the sum of daily ISS scores over the 7 days prior to the visit, ranging from 0 to 21 points. ISS7 = 0 indicates complete resolution of itch.

    Time frame: Time Frame: up to approximately 56 weeks

  6. Change From Baseline in weekly angloedema activity score (AAS7) at each assessment visit.

    The AAS7 is the sum of the daily AAS scores over the 7 days prior to the visit, ranging from 0 to 105 points. AAS7 = 0 indicates no angioedema.

    Time frame: Time Frame: up to approximately 56 weeks

  7. Change From Baseline in Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) at each assessment visit

    The scale consists of 23 items. Each item is scored from 1 to 5 points. The total score is transformed to a scale ranging from 0 to 100, with higher scores indicating a greater impact of the disease on patients' quality of life

    Time frame: up to approximately 56 weeks

  8. The incidence of adverse events during the study

    Incidence and severity of AE from first dose to end of study are recorded

    Time frame: up to approximately 56 weeks

07

Study locations

2 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Mar 2028, 15 months later.

Of 27 industry-sponsored phase 3 interventional studies under Chronic Urticaria, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 31. This study's planned 15 months is below that.

Counting every sponsor, half of 29 studies reached it within 24 months; a quarter within 19 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 18, 2026
StartEst.
Dec 7, 2026
Primary completionEst.
Mar 24, 2028
CompletionEst.
Jan 26, 2029
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07946913
Lead sponsor
Longbio Pharma
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Dec 7, 2026 (estimated)
Primary completion
Mar 24, 2028 (estimated)
Completion
Jan 26, 2029 (estimated)
Last update
Nov 18, 2026

Study contacts

Jie Yang
Contact
yangj@longbiopharma.com
+8621-58372390
Xinghua Gao
principal investigator · First Hospital of China Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LP-003

Start the discussion